ALLIANCE-A021806

NCT04340141 📎

Regimen

Experimental
Perioperative mFOLFIRINOX: 8 cycles neoadjuvant → surgery → 4 cycles adjuvant (total 12 cycles).
Control
Adjuvant-only mFOLFIRINOX: upfront surgery → 12 cycles adjuvant (per PRODIGE-24 schedule).

Population

Strictly resectable PDAC (not borderline), ECOG 0-1, US + Canadian multicenter. Accruing from 2020; enrollment ~145 as of 2023 update.

Key finding

Alliance A021806 is the most important ongoing phase 3 trial addressing whether perioperative (neoadj + adj) mFFX improves OS over adjuvant-only mFFX in strictly resectable PDAC. Results will directly inform the NCCN framework for resectable disease; readout expected ~2027-2028.

Source: PMID 39048905

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.71)